JW LIFESCIENCE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,410 KRW | -0.16% |
|
+0.49% | -3.57% |
| 2023 | JW Lifescience Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2022 | JW Lifescience Corporation(KOSE:A234080) dropped from S&P Global BMI Index | CI |
| Sales 2022 | 189B 139M 191M | Sales 2023 | 207B 152M 209M | Capitalization | 199B 146M 201M |
|---|---|---|---|---|---|
| Net income 2022 | 14.96B 10.98M 15.11M | Net income 2023 | 28.14B 20.66M 28.43M | EV / Sales 2022 | 1.2 x |
| Net Debt 2022 | 38.32B 28.13M 38.71M | Net Debt 2023 | 17.97B 13.19M 18.14M | EV / Sales 2023 | 1.05 x |
| P/E ratio 2022 |
12.6
x | P/E ratio 2023 |
7.08
x | Employees | 256 |
| Yield 2022 |
4.12% | Yield 2023 |
3.89% | Free-Float | 54.08% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.16% | ||
| 1 week | +0.49% | ||
| Current month | -0.32% | ||
| 1 month | -0.64% | ||
| 3 months | -0.64% | ||
| 6 months | -2.90% | ||
| Current year | -3.57% |
1 week
12 330.00
12 600.00
1 month
11 690.0012 600.00
Current year
11 690.0013 550.00
1 year
11 690.0015 160.00
3 years
11 050.0019 700.00
5 years
10 450.0027 200.00
10 years
10 450.0034 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seong-Nam Cha
CEO | Chief Executive Officer | 67 | - |
Jung-Yeol Noh
BRD | Director/Board Member | 57 | - |
Cheol-Won Park
AUD | Comptroller/Controller/Auditor | 80 | 17-02-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyeon-Soon Lee
BRD | Director/Board Member | 73 | - |
Seong-Nam Cha
CEO | Chief Executive Officer | 67 | - |
Jung-Yeol Noh
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 12,410 | -0.16% | 5,592 |
| 24-05-02 | 12,430 | -0.16% | 18,330 |
| 24-04-30 | 12,450 | -0.56% | 23,438 |
| 24-04-29 | 12,520 | +1.38% | 21,701 |
| 24-04-26 | 12,350 | +0.65% | 8,259 |
End-of-day quote Korea S.E., May 02, 2024
More quotes
JW Life Science Co. Ltd. is a Korea-based company primarily engaged in manufacture and distribution of Intravenous (IV) fluid products and infusion solutions. The Company is engaged in manufacture of basic IV fluid including water, electrolytes and glucose; nutrient infusion solution including amino acids, lipids, proteins, vitamins and minerals; and special infusion solution, which is used in special cases. The Company is also engaged in manufacture of total parenteral nutrition (TPN) products and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.57% | 142M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| -3.40% | 157B |
- Stock Market
- Equities
- A234080 Stock
